Open AccessPrognostic Factors in Surgically Managed Gastrointestinal Stromal Tumours
Author(s) -
Xiaojun Wu,
R. X. Zhang,
G. Chen,
YuJen Fang,
Pei-Rong Ding,
Liren Li,
Zhipeng Lü,
Ling-Heng Kong,
Zhizhong Pan,
De Sen Wan
Publication year - 2012
Publication title -
journal of international medical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.421
H-Index - 57
eISSN - 1473-2300
pISSN - 0300-0605
DOI - 10.1177/030006051204000531
Subject(s) - medicine , retrospective cohort study , multivariate analysis , medical record , surgery , imatinib , gist , survival rate , metastasis , overall survival , chemotherapy , stromal cell , oncology , cancer , myeloid leukemia
Objective: To determine prognostic factors associated with survival in patients with surgically managed gastrointestinal stromal tumours (GISTs).Methods: This retrospective study included 374 patients with pathologically confirmed GISTs. Medical records were reviewed and prognostic factors associated with adverse outcomes were determined.Results: A total of 337 patients underwent complete resection with curative intent; 37 underwent incomplete resection. Overall mean survival time was 127.3 months; 5-year survival rate was 70.4%. Multivariate analyses determined that tumour size, risk status (of recurrence or metastasis) and surgical procedure were significant predictive factors for survival. There was a significant difference in the 5-year survival rate between patients who received adjuvant imatinib compared with those who did not (75.1% versus 13.8%).Conclusions: Patients with GISTs managed by surgical resection combined with targeted chemotherapy had a good prognosis. Clinical factors predictive of survival included tumour size, risk status and surgical procedure.